|Bid||0.0001 x 900|
|Ask||3.3600 x 1000|
|Day's Range||3.1743 - 3.2900|
|52 Week Range||2.2500 - 7.0700|
|Beta (3Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center. Under this collaboration, IMV and The Wistar Institute will partner to develop a targeted T cell therapy against the common BRAF cancer mutation, based on peptides identified by the Herlyn lab. Mutations in this gene are the most frequently identified cancer-causing mutations in melanoma and have been identified in various other cancers, including non-Hodgkin lymphoma, colorectal cancer, thyroid cancer, and non-small cell lung and ovarian carcinomas1.
A live webcast of these presentations will be available under “Events, Webcasts and Presentations” in the Investors section of IMV’s website and these webcasts will be available for replay approximately one hour after the presentations. This press release contains forward-looking information under applicable securities law.
DARTMOUTH, Nova Scotia-- -- Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable clinical benefit with progression-free survival in patients with advanced recurrent ovarian cancer Reported positive new data from Phase 2 SPiReL combination study of DPX-Survivac in r/r DLBCL, including long-lasting complete responses The 16 additional patients ...
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV Inc. , a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor con
TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV’s lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda® (pembrolizumab). The trial is designed to evaluate the safety and efficacy of the combination immunotherapy in patients with persistent or recurrent/refractory diffuse large B-cell lymphoma (DLBCL). “We are highly encouraged by the level of activity that we are observing with the combination of DPX-Survivac and Keytruda in these patients with DLBCL,” said Frederic Ors, IMV’s Chief Executive Officer.
TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Wednesday, June 12, 2019, at 8:00 a.m. ET. This call will provide an update on its ongoing phase 2 clinical trials with Merck’s Keytruda® in diffuse large B-cell lymphoma (DLBCL). The webcast will be recorded and made available on the IMV website for 30 days following the call.
TSX: IMV), a clinical stage immuno-oncology corporation, today announced that investigators shared new positive data for its DeCidE1 (DPX-Survivac with low dose Cyclophosphamide and Epacadostat) clinical trial at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting. These new data are from the ongoing Phase 1b/2 trial evaluating the safety and efficacy of IMV’s lead candidate DPX-Survivac and intermittent low-dose cyclophosphamide (CPA), with and without Incyte’s IDO1 enzyme inhibitor epacadostat, in patients with advanced recurrent ovarian cancer.
TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the American Society of Clinical Oncology (ASCO) has published an abstract on the Company’s clinical study evaluating its lead candidate, DPX-Survivac, in recurrent advanced ovarian cancer. The abstract was released online on the ASCO website yesterday in advance of ASCO’s annual meeting in Chicago, Illinois, taking place May 31 – June 4, 2019.
IMV Inc. , a clinical stage immunotherapy company , today announced the voting results from its Annual and Special Meeting of Shareholders held on Thursday May 9, 2019.
IMV Inc. , a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019.
TSX: IMV), a clinical stage immuno-oncology corporation, today joins with World Ovarian Cancer Coalition and Ovarian Cancer Canada in recognizing World Ovarian Cancer Day (WOCD). This initiative aims to raise awareness of, and bring hope to, the global challenges faced by women living with a diagnosis of ovarian cancer. “Ovarian cancer remains one of the most underserved, difficult-to-treat forms of the disease,” said Frederic Ors, Chief Executive Officer at IMV Inc.
TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, May 10, 2019 at 8:00 a.m. ET to discuss the company’s first quarter 2019 financial and operational results. The webcast will be recorded and will then be available on the IMV website for 30 days following the call. IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
TSX: IMV), a clinical stage immuno-oncology corporation, today announced that two of its abstracts have been accepted for presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 31 – June 4 in Chicago, IL. “Despite advances in other cancer treatment regimens, ovarian cancer remains a particularly difficult-to-treat disease, and one that represents one of the most underserved areas of the treatment landscape,” said Frederic Ors, Chief Executive Officer at IMV.
TSX: IMV), a clinical stage immuno-oncology company, today issued the following statement regarding recent market activity. In recent weeks, shares of IMV Inc. have come under unwarranted market pressure and the management team believes it is prudent to provide a mid-quarter update on the health of the business and the Company’s upcoming Q2 clinical milestones. “From a financial and clinical results standpoint, IMV has recently achieved noteworthy milestones and, based on clinical results observed thus far, our long term outlook remains unchanged and very promising,” said Frederic Ors, Chief Executive Officer.
IMV Inc. , a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference, which will be held from April 30 to May 1, 2019 in Toronto, Ontario.
TSX: IMV), a clinical stage immuno-oncology corporation, today announced that preclinical research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 demonstrated how the mechanism of action (MOA) of IMV’s proprietary DPX technology can enhance a broad spectrum of immune cell infiltration into tumors, which included T cells, Natural Killer (NK) cells, and macrophages. Analyses also revealed the differentiated characteristics of the immune cell responses and the potential implications for enhanced anti-tumor efficacy.
TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. “This initial phase 2 data confirms the earlier trends we saw in the phase 1b portion of the study,” said Frederic Ors, Chief Executive Officer. “It supports the potential of DPX-Survivac as a monotherapy and the use of our patient selection strategy.
DARTMOUTH, Nova Scotia-- -- Attained multiple milestones in DECIDE1/2 clinical program in advanced ovarian cancer Achieved initial positive data from phase 2 clinical trial in DLBCL with Merck Initiated a phase 2 basket trial across five indications under a collaboration with Merck Listed on Nasdaq and changed Corporation name to better reflect inherent value proposition Will host conference call tomorrow ...
TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Canadian bioresearch consortium CQDM has awarded a grant to a collaboration among IMV, Centre de recherche du CHU de Québec-Université Laval, and La Fondation du CHU de Québec (FCHUQc).